NFL Biosciences S.A.
ALNFL.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.17 | 1.46 | -0.03 | -0.05 |
| FCF Yield | 0.00% | 0.00% | 1.02% | 0.69% |
| EV / EBITDA | -6.60 | -2.32 | -3.32 | -8.93 |
| Quality | ||||
| ROIC | -180.34% | -1,082.19% | -277.54% | -22.52% |
| Gross Margin | -145,963.04% | -28.03% | 0.00% | -1,360,853.85% |
| Cash Conversion Ratio | – | – | -0.04 | -0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 1,624.50% | -100.00% | – |
| Free Cash Flow Growth | 0.00% | -100.00% | 20.56% | 3.68% |
| Safety | ||||
| Net Debt / EBITDA | 0.71 | 0.56 | 0.35 | 2.75 |
| Interest Coverage | -9,177.93 | -680.97 | -6,112.64 | -1,676.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 8,397,506.29 | -12,064.65 | -193.79 | 2,058,348.90 |